Skip to main content

Katarya (hydrocortisone / hydroquinone / tretinoin topical) Disease Interactions

There are 7 disease interactions with Katarya (hydrocortisone / hydroquinone / tretinoin topical):

Major

Retinoid/retinoid-like topical (applies to Katarya) eczema

Major Potential Hazard, High plausibility.

Topical retinoids may cause severe irritation on eczematous skin. Therapy with topical retinoids should be avoided on abraded or eczematous skin.

References

  1. "Product Information. Differin (adapalene topical)." Galderma Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Tazorac (tazarotene topical)." Allergan Inc, Irvine, CA.
  3. "Product Information. Retin-A (tretinoin)." Ortho Pharmaceutical Corporation, Raritan, NJ.
Moderate

Retinoid/retinoid-like topical (applies to Katarya) sunburn

Moderate Potential Hazard, High plausibility.

Retinoid-like products can cause extreme irritation when applied to sunburned skin. Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.

References

  1. "Product Information. Differin (adapalene topical)." Galderma Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Tazorac (tazarotene topical)." Allergan Inc, Irvine, CA.
  3. "Product Information. Retin-A (tretinoin)." Ortho Pharmaceutical Corporation, Raritan, NJ.
  4. Rosenbluth M "Adverse reaction to retin-A." J Am Dent Assoc 119 (1989): 346
View all 4 references
Moderate

Topical corticosteroids (applies to Katarya) diabetes

Moderate Potential Hazard, Low plausibility. Applicable conditions: Abnormal Glucose Tolerance, Diabetes Mellitus

Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia. Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration. Use of occlusive dressings over the applied areas may also increase percutaneous absorption. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.

References

  1. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  2. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  3. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  4. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  5. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  6. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  7. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  8. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  9. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  10. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  11. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  12. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  13. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  14. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  15. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  16. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  17. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  18. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  19. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  20. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  21. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  22. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  23. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
View all 23 references
Moderate

Topical corticosteroids (applies to Katarya) diaper rash

Moderate Potential Hazard, High plausibility.

Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing's syndrome and intracranial hypertension because of their larger skin surface to body mass ratios. If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.

References

  1. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  2. Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979): 362-3
  3. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  4. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  5. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  6. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  7. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  8. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  9. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  10. Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987): 422-4
  11. Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983): 475-80
  12. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  13. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  14. Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993): 501-3
  15. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  16. Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995): 950-5
  17. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  18. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  19. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  20. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983): 1130-1
  21. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing's syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982): 274-5
  22. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  23. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  24. Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991): 61-2
  25. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  26. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  27. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22
  28. Nathan AW, Rose GL "Fatal iatrogenic Cushing's syndrome." Lancet 1 (1979): 207
  29. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  30. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  31. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
  32. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  33. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976): 612-3
  34. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  35. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  36. Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977): 1196-202
  37. Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983): 59-71
View all 37 references
Moderate

Topical corticosteroids (applies to Katarya) hyperadrenocorticism

Moderate Potential Hazard, Low plausibility. Applicable conditions: Liver Disease

The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism. Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression. Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Patients with an altered skin barrier or liver failure are also at increased risk. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.

References

  1. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976): 612-3
  2. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  3. Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing's syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982): 274-5
  4. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  5. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  6. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  7. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  8. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  9. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  10. Nathan AW, Rose GL "Fatal iatrogenic Cushing's syndrome." Lancet 1 (1979): 207
  11. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  12. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  13. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  14. Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983): 475-80
  15. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  16. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  17. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  18. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  19. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  20. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  21. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  22. Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991): 61-2
  23. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  24. Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996): 18-22
  25. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  26. Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990): 107-11
  27. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  28. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  29. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  30. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  31. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
  32. Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983): 1130-1
View all 32 references
Moderate

Topical corticosteroids (applies to Katarya) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, Tuberculosis -- Latent

Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used. Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. Occlusive dressings should not be used in patients with skin infection.

References

  1. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  3. Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971): 421-5
  4. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  5. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  6. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  7. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  8. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
  9. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  10. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  11. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  12. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  13. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  14. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  15. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  16. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  17. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  18. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  19. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  20. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  21. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  22. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  23. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  24. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
View all 24 references
Moderate

Topical corticosteroids (applies to Katarya) ocular toxicities

Moderate Potential Hazard, Low plausibility. Applicable conditions: Cataracts, Glaucoma/Intraocular Hypertension

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.

References

  1. "Product Information. Cyclocort (amcinonide topical)." Fujisawa, Deerfield, IL.
  2. "Product Information. Lidex (fluocinonide)." Syntex Laboratories Inc, Palo Alto, CA.
  3. "Product Information. Psorcon (diflorasone topical)." Rhone-Poulenc Rorer, Collegeville, PA.
  4. "Product Information. Desowen (desonide topical)." Galderma Laboratories Inc, Fort Worth, TX.
  5. "Product Information. Halog (halcinonide)." Bristol-Myers Squibb, Princeton, NJ.
  6. "Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc, Palo Alto, CA.
  7. Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983): 878-81
  8. "Product Information. Temovate (clobetasol)." Glaxo Wellcome, Research Triangle Park, NC.
  9. "Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa, Deerfield, IL.
  10. "Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals, Titusville, NJ.
  11. Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973): 11 passim
  12. "Product Information. Proctocream HC 2.5% (hydrocortisone topical)." Schwarz Pharma, Mequon, WI.
  13. Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976): 492-5
  14. Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977): 522
  15. "Product Information. Elocon (mometasone topical)." Schering Corporation, Kenilworth, NJ.
  16. "Product Information. Topicort (desoximetasone topical)." Hoechst Marioin-Roussel Inc, Kansas City, MO.
  17. "Product Information. Decadron Phosphate, Topical (dexamethasone topical)." Merck & Co, Inc, West Point, PA.
  18. "Product Information. Pandel (hydrocortisone topical)." Savage Laboratories, Melville, NY.
  19. Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993): 664-6
  20. "Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome, Research Triangle Pk, NC.
  21. Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976): 207-8
  22. "Product Information. Cutivate (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.
  23. "Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc, Corona, CA.
  24. "Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation, Buffalo, NY.
  25. "Product Information. Ultravate (halobetasol)." Bristol-Myers Squibb, Princeton, NJ.
  26. "Product Information. Cloderm (clocortolone topical)" Hermal Pharmaceutical Labs Inc, Delmar, NY.
  27. "Product Information. Diprolene (betamethasone topical)." Schering Laboratories, Kenilworth, NJ.
View all 27 references

Katarya (hydrocortisone / hydroquinone / tretinoin topical) drug interactions

There are 56 drug interactions with Katarya (hydrocortisone / hydroquinone / tretinoin topical)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.